Nowak Anna, Wicik Zofia, Wolska Marta, Shahzadi Andleeb, Szwed Piotr, Jarosz-Popek Joanna, Palatini Jeffrey, Postula Marek, Czlonkowska Anna, Mirowska-Guzel Dagmara, Eyileten Ceren
Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B str., 02-097, Warsaw, Poland.
Doctoral School, Medical University of Warsaw, Warsaw, Poland.
Mol Neurobiol. 2022 Aug;59(8):4651-4668. doi: 10.1007/s12035-022-02854-y. Epub 2022 May 19.
Multiple sclerosis (MS) is a central nervous system chronic neuroinflammatory disease followed by neurodegeneration. The diagnosis is based on clinical presentation, cerebrospinal fluid testing and magnetic resonance imagining. There is still a lack of a diagnostic blood-based biomarker for MS. Due to the cost and difficulty of diagnosis, new and more easily accessible methods are being sought. New biomarkers should also allow for early diagnosis. Additionally, the treatment of MS should lead to the personalization of the therapy. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as well as their target genes participate in pathophysiology processes in MS. Although the detailed mechanism of action of non-coding RNAs (ncRNAs, including miRNAs and lncRNAs) on neuroinflammation in MS has not been fully explained, several studies were conducted aiming to analyse their impact in MS. In this article, we review up-to-date knowledge on the latest research concerning the ncRNAs in MS and evaluate their role in neuroinflammation. We also point out the most promising ncRNAs which may be promising in MS as diagnostic and prognostic biomarkers.
多发性硬化症(MS)是一种中枢神经系统慢性神经炎症性疾病,随后会发生神经退行性变。诊断基于临床表现、脑脊液检测和磁共振成像。目前仍缺乏用于MS诊断的基于血液的生物标志物。由于诊断的成本和难度,人们正在寻找新的、更容易获得的方法。新的生物标志物还应有助于早期诊断。此外,MS的治疗应实现个性化治疗。微小RNA(miRNA)和长链非编码RNA(lncRNA)及其靶基因参与了MS的病理生理过程。尽管非编码RNA(ncRNA,包括miRNA和lncRNA)对MS神经炎症的详细作用机制尚未完全阐明,但已开展了多项研究来分析它们在MS中的影响。在本文中,我们综述了有关MS中ncRNA的最新研究的最新知识,并评估了它们在神经炎症中的作用。我们还指出了在MS中作为诊断和预后生物标志物最有前景的ncRNA。